Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
https://doi.org/10.21518/2079-701X-2018-19-56-60
Abstract
The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactions allows the use of nab-paclitaxel in patients who had reactions with the introduction of traditional taxanes and in the presence of contraindications to corticosteroids premedication. The absence of cross-resistance makes possible to prescribe nabpaclitaxel in patients who had progression on treatment with paclitaxel and docetaxel. The cases of effective use of the drug from our own practice are presented.
About the Authors
E. I. Borisova
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
S. P. Gutorov
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
G. V. Vyshinskaya
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
N. V. Dobrova
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
M. E. Abramov
Blokhin National Medical Research Cancer Centre, Federal State Budgetary Institution Н.Н. of the Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
References
1. The state of cancer care in Russia, 2017. Under the editorship of Kaprina AD, Starinsky VV, Petrova GV. M.: Moscow. Hertsen Moscow Oncology Research Center - branch of FSBI NMRRC of the Ministry of Health of Russia, 2018, 116 p.
2. Jones S, Erban J, Overmoyer B, Budd G, Hutchins L, Lower E et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 2005, 23: 5542–5551.
3. Scheff RJ. Breast cancer and the new taxanes: focus on nab-paclitaxel. Commun Oncol, 2008, 5(suppl 8): 7–13.
4. Ibrahim N, Desai N, Legha S, Soon-Shiong P, Theriault R, Rivera E et al. Phase I and pharmacokinetic study of ABI-007, a cremophorfree, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res, 2002, 8: 1038–1044.
5. Nyman D, Campbell K, Hersh E, Long K, Richardson K, Trieu V et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced non-hematologic malignancies. J Clin Oncol, 2005, 23: 7785–7793.
6. Gardner E, Dahut W, Scripture C, Jones J, Aragon-Ching J, Desa N et al. Randomized crossover pharmacokinetic study of solventbased paclitaxel and nab-paclitaxel. Clin Cancer Res, 2008, 14: 4200–4205.
7. Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 2005, 23: 7794–7803.
8. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A et al. Significantly longer progression-free survival with nabpaclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol, 2009, 27: 3611–3619.
9. Rugo H, Barry W, Moreno-Aspitia A, Lyss A and Cirrincione C. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as firstline chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol, 2015, 33: 2361–2369.
10. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSeptoGBG 69): a randomised, phase 3 trial. Lancet Oncol, 2016 Mar, 17(3): 345-56.
11. Hamilton E, Kimmick G, Hopkins J, Marcom P, Rocha G, Welch R et al. Nab-paclitaxel/bevacizumab/ carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer, 2013, 13: 413–420.
12. Blum J, Savin M, Edelman G, Pippen J, Robert N, Geister B et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer, 2007, 7: 850–856.
13. Palumbo R, Sottotetti F, Bernardo A. Targeted chemotherapy with nanoparticle albuminbound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? Ther Adv Med Oncol, 2016, 8(3): 209–229.
Review
For citations:
Borisova EI, Gutorov SP, Vyshinskaya GV, Dobrova NV, Abramov ME. Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience. Meditsinskiy sovet = Medical Council. 2018;(19):56-60. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-56-60
Views:
1099
Email this article 